Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #7835
Reference
Drug alert 10/2023
Name
Drug alert class 4 – 10 2023 – Class 4 medicines defect information – caution in use - Macarthys Laboratories t/a Martindale Pharma (an Ethypharm Group Company) – Venlafaxine XL 150mg prolonged release tablets
Categories
Scottish Government
Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
DRUGS
SAFETY
RISKS
PHARMACEUTICAL INDUSTRY
MEDICINES RECALL
Description
Additional to the batches included in the previous Class 4 Medicines Notification, Martindale Pharma has made the MHRA aware that the GTIN in the 2D barcode and the printed variable data represents the branded version of the product (Venlalic® XL prolonged-release tablets). It should instead reflect the generic name: Venlafaxine XL prolonged-release tablets. The code under the preprinted barcode is correct.
Contact Name
Irene Fazakerley
Contact Email
Contact Address
Contact Phone
Created
2023-03-16 00:00:00
Click to go back to homepage